Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD22 CAR T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
NCT02315612Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2014
- Primary completion
- Apr 2019
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CD22-CAR-T in B cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (2 arms), sponsored by National Cancer Institute. Primary endpoints: Toxicity and Response at 6 months. Started Dec 2014; status: completed.
02
Drugs
CD22-CAR-T
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT02315612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02315612.